Your browser is no longer supported. Please, upgrade your browser.
Surface Oncology, Inc.
Index- P/E73.55 EPS (ttm)0.11 Insider Own1.00% Shs Outstand41.62M Perf Week-0.63%
Market Cap319.60M Forward P/E- EPS next Y-1.36 Insider Trans-89.40% Shs Float36.17M Perf Month9.92%
Income21.20M PEG- EPS next Q-0.33 Inst Own57.80% Short Float12.28% Perf Quarter-29.98%
Sales89.20M P/S3.58 EPS this Y179.10% Inst Trans1.04% Short Ratio2.81 Perf Half Y-13.42%
Book/sh3.82 P/B2.06 EPS next Y-9.20% ROA11.60% Target Price- Perf Year201.53%
Cash/sh4.21 P/C1.87 EPS next 5Y- ROE17.00% 52W Range2.45 - 14.40 Perf YTD-14.83%
Dividend- P/FCF- EPS past 5Y- ROI34.80% 52W High-45.35% Beta-
Dividend %- Quick Ratio12.00 Sales past 5Y- Gross Margin- 52W Low221.22% ATR0.53
Employees51 Current Ratio12.00 Sales Q/Q-95.90% Oper. Margin24.90% RSI (14)54.42 Volatility8.77% 7.40%
OptionableYes Debt/Eq0.09 EPS Q/Q-151.20% Profit Margin23.80% Rel Volume0.82 Prev Close7.36
ShortableYes LT Debt/Eq0.08 Earnings- Payout0.00% Avg Volume1.58M Price7.87
Recom1.60 SMA208.98% SMA500.92% SMA200-5.65% Volume1,294,475 Change6.93%
Sep-04-20Initiated H.C. Wainwright Buy $11
Aug-28-20Initiated Wedbush Outperform $12
Sep-19-18Initiated Robert W. Baird Outperform
May-14-18Initiated Goldman Neutral $17
May-14-18Initiated Evercore ISI Outperform $26
May-16-21 06:20AM  
May-05-21 06:45AM  
Apr-28-21 04:05PM  
Apr-27-21 07:00AM  
Apr-19-21 07:00AM  
Apr-09-21 07:53AM  
Apr-08-21 07:32AM  
Mar-31-21 11:12AM  
Mar-30-21 06:11PM  
Mar-23-21 11:47PM  
Mar-18-21 08:00AM  
Mar-17-21 08:01AM  
Mar-10-21 04:35PM  
Mar-09-21 08:25AM  
Mar-05-21 08:48AM  
Mar-02-21 12:30PM  
Feb-24-21 07:00AM  
Feb-23-21 07:25AM  
Feb-22-21 06:21AM  
Feb-11-21 07:00AM  
Jan-19-21 03:25PM  
Jan-13-21 08:39AM  
Jan-11-21 06:00AM  
Dec-22-20 12:20PM  
Dec-17-20 03:35PM  
Dec-14-20 07:07AM  
Dec-07-20 08:29AM  
Nov-25-20 07:00AM  
Nov-15-20 08:39AM  
Nov-13-20 07:05AM  
Nov-11-20 07:00AM  
Nov-10-20 06:20AM  
Nov-09-20 04:25PM  
Nov-05-20 09:43AM  
Oct-26-20 04:05PM  
Oct-20-20 01:03PM  
Oct-19-20 12:32PM  
Oct-12-20 03:41PM  
Sep-16-20 05:05PM  
Sep-15-20 07:23AM  
Sep-11-20 03:00PM  
Sep-09-20 01:15PM  
Sep-04-20 09:38AM  
Sep-02-20 08:52AM  
Aug-28-20 10:16AM  
Aug-19-20 01:56PM  
Aug-11-20 06:30AM  
Aug-05-20 11:59AM  
Jun-12-20 09:45AM  
Jun-10-20 08:12PM  
May-28-20 04:10PM  
May-20-20 11:28AM  
May-15-20 11:46AM  
May-14-20 07:30AM  
May-13-20 08:00AM  
May-12-20 06:20AM  
May-07-20 12:30PM  
Apr-23-20 08:00AM  
Mar-17-20 08:00AM  
Mar-12-20 10:39AM  
Mar-10-20 06:20AM  
Mar-06-20 11:30AM  
Feb-25-20 04:05PM  
Feb-19-20 11:30AM  
Feb-04-20 06:58AM  
Jan-28-20 07:12AM  
Jan-27-20 04:05PM  
Dec-23-19 10:24AM  
Dec-09-19 05:45PM  
Nov-26-19 11:07AM  
Nov-25-19 08:00AM  
Nov-18-19 06:30AM  
Nov-12-19 07:45AM  
Nov-07-19 08:00AM  
Oct-26-19 06:25PM  
Oct-07-19 07:00AM  
Sep-23-19 12:50PM  
Sep-18-19 05:55PM  
Sep-17-19 05:25PM  
Sep-03-19 04:05PM  
Aug-28-19 10:45AM  
Aug-27-19 08:00AM  
Aug-21-19 08:45PM  
Aug-20-19 01:15PM  
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSS ROBERT W.Chief Medical OfficerFeb 16Sale11.351,00011,35088,000Feb 18 08:00 PM
Goater JeffChief Executive OfficerFeb 08Option Exercise3.182,5007,950264,500Feb 09 08:00 PM
FEES JESSICASee RemarksFeb 08Sale12.451,50018,67599,183Feb 09 08:00 PM
Goater JeffChief Executive OfficerFeb 08Sale12.502,50031,250262,000Feb 09 08:00 PM
Goater JeffChief Executive OfficerFeb 01Option Exercise3.182,5007,950264,500Feb 03 08:00 PM
FEES JESSICASee RemarksFeb 01Sale11.191,50016,785100,683Feb 03 08:00 PM
Goater JeffChief Executive OfficerFeb 01Sale10.692,50026,718262,000Feb 03 08:00 PM
Goater JeffChief Executive OfficerJan 19Option Exercise3.185,00015,900267,000Jan 21 08:17 PM
Goater JeffChief Executive OfficerJan 19Sale13.005,00065,000262,000Jan 21 08:17 PM
ROSS ROBERT W.Chief Medical OfficerJan 15Sale12.252,00024,50089,000Jan 15 08:00 PM
ROSS ROBERT W.Chief Medical OfficerJan 14Sale11.957,00083,65091,000Jan 15 08:00 PM
Atlas Venture Fund IX, L.P.10% OwnerDec 17Sale18.101,700,00030,770,0002,945,453Dec 21 01:32 PM
GRAYZEL DAVID S.DirectorDec 17Sale18.101,700,00030,770,0002,945,453Dec 21 01:32 PM
ROSS ROBERT W.Chief Medical OfficerDec 15Sale10.481,00010,48098,000Dec 17 08:00 PM
ROSS ROBERT W.Chief Medical OfficerDec 11Sale10.051,40514,12099,000Dec 15 08:00 PM
FEES JESSICASee RemarksNov 25Option Exercise5.061,3836,996102,183Nov 27 08:00 PM
ROSS ROBERT W.Chief Medical OfficerNov 11Sale10.055955,980100,405Nov 13 08:00 PM
FEES JESSICASee RemarksOct 28Option Exercise4.144,89520,262100,800Oct 30 08:30 PM
ROSS ROBERT W.Chief Medical OfficerOct 14Sale10.054,00040,200101,000Oct 16 08:02 PM
EcoR1 Capital, LLC10% OwnerSep 01Sale7.14332,7802,376,6814,701,081Sep 03 04:17 PM
New Enterprise Associates 14, 10% OwnerMay 20Sale3.66420,0001,535,5622,892,877May 22 04:56 PM